On the basis of region:-
North America (United States, Canada, Mexico)
Europe (Germany, France, UK, Italy, Russia)
Asia-Pacific (China, Japan, Korea, India, South East Asia)
South America (Brazil, Colombia)
Adapt their financial planning after market stability sets in to press forward.
Create stability by making appropriate decisions for individual business groups, goods, and service lines about capital and expenditure.
To prevent future disaster scenarios, conceptualize scenario-based planning.
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
Health
your username
2 hours ago On Wednesday in the District of Delaware, Shilpa Pharma Inc. filed a complaint against Novartis Pharmaceuticals Corporation, alleging that the defendant’s drug Gilenya infringes on one of the plaintiff’s patents.
Shilpa is the assignee of United States Patent No. 9,266,816 (the ’816 patent), “Fingolimod Polymorphs and Their Processes,” according to the complaint.
Novartis holds New Drug Application (NDA) No. 022527 for Gilenya capsules in 0.5 and 0.25 mg strengths, which is listed in the Food and Drug Administration (FDA)’s drug patent database,
Orange Book. The active ingredient in Gilenya is fingolimod hydrochloride, which is used to treat multiple sclerosis in patients 10 years and older.
DOJ Introduces Novel Theories of Liability and Requires Unprecedented Controls in Speaker Program Settlement | Skadden, Arps, Slate, Meagher & Flom LLP jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
? Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment Basel, 13 April 2020 - Roche